{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:41:16Z","timestamp":1774971676865,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40266-026-01294-w","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T15:20:37Z","timestamp":1774538437000},"page":"307-311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Managing Acute Severe Ulcerative Colitis in the Older Patient: A Growing Concern"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6159-7478","authenticated-orcid":false,"given":"Walter","family":"Fries","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Costantino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Viola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"1294_CR1","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","volume":"158","author":"JD Feuerstein","year":"2020","unstructured":"Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158:1450\u201361.","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"1294_CR2","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2024-334395","volume":"74","author":"GW Moran","year":"2025","unstructured":"Moran GW, Gordon M, Sinopolou V, et al. British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025. Gut. 2025;74(Suppl 2):s1\u2013101.","journal-title":"Gut"},{"key":"1294_CR3","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/ecco-jcc\/jjv059","volume":"9","author":"S Taleban","year":"2015","unstructured":"Taleban S, Colombel JF, Mohler MJ, et al. Inflammatory bowel disease and the elderly: a review. J Crohns Colitis. 2015;9:507\u201315.","journal-title":"J Crohns Colitis"},{"key":"1294_CR4","unstructured":"World Health Organization. Ageing and health. 2022. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/ageing-and-health. Accessed 31 Jan 2026."},{"key":"1294_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/MCG.0000000000001458","volume":"56","author":"J Schwartz","year":"2022","unstructured":"Schwartz J, Stein DJ, Lipcsey M, et al. High rates of mortality in geriatric patients admitted for inflammatory bowel disease management. J Clin Gastroenterol. 2022;56:20\u20136.","journal-title":"J Clin Gastroenterol"},{"key":"1294_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.dld.2016.09.006","volume":"49","author":"W Fries","year":"2017","unstructured":"Fries W, Viola A, Manetti N, et al. Disease patterns in late-onset ulcerative colitis: results from the IG-IBD \u201cAGED\u201d study. Dig Liver Dis. 2017;49:17\u201323.","journal-title":"Dig Liver Dis"},{"key":"1294_CR7","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1016\/j.cgh.2020.02.048","volume":"18","author":"JJ Rozich","year":"2020","unstructured":"Rozich JJ, Dulai PS, Fumery M, et al. Progression of elderly-onset inflammatory bowel diseases: a systematic review and meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2020;18:2437-47.e6.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1294_CR8","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1093\/ecco-jcc\/jjad183","volume":"18","author":"T Boyd","year":"2024","unstructured":"Boyd T, Araka EB, Kochar B, et al. Differences in management and outcomes of older and younger adults with acute severe ulcerative colitis. J Crohns Colitis. 2024;18:570\u20137.","journal-title":"J Crohns Colitis"},{"key":"1294_CR9","doi-asserted-by":"publisher","first-page":"S-158","DOI":"10.1016\/S0016-5085(24)00855-2","volume":"166","author":"NM Chowla","year":"2024","unstructured":"Chowla NM, Tariq R, Hashash JG, et al. Outcome of acute severe ulcerative colitis in elderly patients. Gastroenterology. 2024;166:S-158 (abstract).","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"1294_CR10","doi-asserted-by":"publisher","first-page":"i1269","DOI":"10.1093\/ecco-jcc\/jjae190.0821","volume":"19","author":"R Tejero Jurado","year":"2025","unstructured":"Tejero Jurado R, El Fallous El Mraghid M, Carrillo Cubero B, et al. Impact of age and comorbidities on treatment outcomes and mortality in patients admitted for ulcerative colitis flares: a 20-year retrospective cohort study. J Crohns Colitis. 2025;19(Suppl 1):i1269 (abstract).","journal-title":"J Crohns Colitis"},{"issue":"Suppl 1","key":"1294_CR11","doi-asserted-by":"publisher","first-page":"i1529","DOI":"10.1093\/ecco-jcc\/jjae190.0970","volume":"19","author":"J Ollech","year":"2025","unstructured":"Ollech J, Lev Kolnik R, Dotan I, et al. Comparison of disease severity, treatment, and outcomes in elderly and younger patients hospitalized with acute severe ulcerative colitis (ASUC). J Crohns Colitis. 2025;19(Suppl 1):i1529 (abstract).","journal-title":"J Crohns Colitis"},{"key":"1294_CR12","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3390\/nu18030383","volume":"18","author":"A Favale","year":"2026","unstructured":"Favale A, Orr\u00f9 V, Lutzu N, et al. Optimizing malnutrition risk detection in inflammatory bowel disease: a longitudinal analysis of serial nutritional screening tools. Nutrients. 2026;18:383.","journal-title":"Nutrients"},{"key":"1294_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/MLR.0000000000001962","volume":"62","author":"T Gilbert","year":"2024","unstructured":"Gilbert T, Cordier Q, Polazzi S, et al. Combining the Hospital Frailty Risk Score with the Charlson and Elixhauser multimorbidity indices to identify older patients at risk of poor outcomes in acute care. Med Care. 2024;62:117\u201324.","journal-title":"Med Care"},{"key":"1294_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","volume":"1","author":"JG Williams","year":"2016","unstructured":"Williams JG, Alam MF, Alrubaiy L, et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomized trial. Lancet Gastroenterol Hepatol. 2016;1:15\u201324.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1294_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1136\/gutjnl-2016-313060","volume":"67","author":"D Laharie","year":"2018","unstructured":"Laharie D, Bourreille A, Branche J, et al. Long-term outcome of patients with steroid-refractory acute severe ulcerative colitis treated with ciclosporin or infliximab. Gut. 2018;67:237\u201343.","journal-title":"Gut"},{"key":"1294_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000546511","volume":"10","author":"F Grob","year":"2025","unstructured":"Grob F, H\u00e4berling I, Novacek G, et al. Long-term outcome of ciclosporin and infliximab as rescue therapy in steroid-refractory acute severe ulcerative colitis. Inflamm Intest Dis. 2025;10:155\u201360.","journal-title":"Inflamm Intest Dis."},{"key":"1294_CR17","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1111\/apt.16865","volume":"55","author":"S Okabayashi","year":"2022","unstructured":"Okabayashi S, Yamazaki H, Tominaga K, et al. Lower effectiveness of intravenous steroid treatment for moderate-to-severe ulcerative colitis in hospitalized patients with older onset: a multicentre cohort study. Aliment Pharmacol Ther. 2022;55:1569\u201380.","journal-title":"Aliment Pharmacol Ther"},{"key":"1294_CR18","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1097\/01.MIB.0000436961.08029.17","volume":"19","author":"NK Weber","year":"2013","unstructured":"Weber NK, Bruining DH, Loftus EV Jr, et al. Comparative outcomes of younger and older hospitalized patients with inflammatory bowel disease treated with corticosteroids. Inflamm Bowel Dis. 2013;19:2644\u201351.","journal-title":"Inflamm Bowel Dis"},{"key":"1294_CR19","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.3748\/wjg.v29.i16.2469","volume":"29","author":"D Subhaharan","year":"2023","unstructured":"Subhaharan D, Ramaswamy PK, Willmann L, et al. Older adults with acute severe ulcerative colitis have similar steroid non-response and colectomy rates as younger adults. World J Gastroenterol. 2023;29:2469\u201378.","journal-title":"World J Gastroenterol"},{"key":"1294_CR20","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1136\/gut.38.6.905","volume":"38","author":"SP Travis","year":"1996","unstructured":"Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905\u201310.","journal-title":"Gut"},{"key":"1294_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf131","volume":"19","author":"SK Vuyyuru","year":"2025","unstructured":"Vuyyuru SK, Alphonsus L, De Silva TA, et al. Day 3 Oxford criteria predict steroid non-response for acute severe ulcerative colitis in the post-biologic era. J Crohns Colitis. 2025;19:jjaf131 (in press).","journal-title":"J Crohns Colitis"},{"key":"1294_CR22","doi-asserted-by":"publisher","first-page":"6476","DOI":"10.3390\/jcm14186476","volume":"14","author":"EM Mastoridou","year":"2025","unstructured":"Mastoridou EM, Fousekis FS, Sakellariou XM, et al. The cardiovascular effects of inflammatory bowel disease therapy with biologics and small molecules: a comprehensive review. J Clin Med. 2025;14:6476.","journal-title":"J Clin Med"},{"key":"1294_CR23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.4330\/wjc.v15.i5.217","volume":"15","author":"TG Grillo","year":"2023","unstructured":"Grillo TG, Silveira CFDSMP, Quaglio AEV, et al. Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: a review of the literature. World J Cardiol. 2023;15:217\u201328.","journal-title":"World J Cardiol"},{"key":"1294_CR24","unstructured":"ClinicalTrials.gov. Study NCT02770040. https:\/\/www.clinicaltrials.gov\/study\/NCT02770040. Accessed 20 Sept 2025."},{"key":"1294_CR25","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/ajg.2016.7","volume":"111","author":"N Narula","year":"2016","unstructured":"Narula N, Marshall JK, Colombel JF. Systematic review and meta-analysis: infliximab or ciclosporin as rescue therapy in patients with severe ulcerative colitis refractory to steroids. Am J Gastroenterol. 2016;111:477\u201391.","journal-title":"Am J Gastroenterol"},{"key":"1294_CR26","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.dld.2017.01.141","volume":"49","author":"L Biancone","year":"2017","unstructured":"Biancone L, Annese V, Ardizzone S, et al. Safety of treatments for inflammatory bowel disease: clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Dig Liver Dis. 2017;49:338\u201358.","journal-title":"Dig Liver Dis"},{"key":"1294_CR27","first-page":"S1542-3565(25)0","volume":"23","author":"S Honap","year":"2025","unstructured":"Honap S, St-Pierre J, Colwill M, et al. Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2025;23:S1542-3565(25)00639-1 (in press).","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1294_CR28","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.14309\/ajg.0000000000002635","volume":"119","author":"A Singh","year":"2024","unstructured":"Singh A, Goyal MK, Midha V, et al. Tofacitinib in acute severe ulcerative colitis (TACOS): a randomized controlled trial. Am J Gastroenterol. 2024;119:1365\u201372.","journal-title":"Am J Gastroenterol"},{"key":"1294_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf021","volume":"19","author":"JP Gisbert","year":"2025","unstructured":"Gisbert JP, Chaparro M. Janus kinase inhibitors in the management of acute severe ulcerative colitis: a comprehensive review. J Crohns Colitis. 2025;19:jjaf021 (in press).","journal-title":"J Crohns Colitis"},{"key":"1294_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-025-09647-y","author":"NM Garcia","year":"2026","unstructured":"Garcia NM, Memel Z, Zou Y, et al. Upadacitinib is safe and effective in older adults: a real-world experience comparing safety and efficacy in younger versus older adults with inflammatory bowel disease. Dig Dis Sci. 2026. https:\/\/doi.org\/10.1007\/s10620-025-09647-y.","journal-title":"Dig Dis Sci"},{"key":"1294_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000549088","volume":"11","author":"T Alsaleh","year":"2025","unstructured":"Alsaleh T, Mohammed A, Farooq A, et al. Upadacitinib versus tofacitinib in the management of ulcerative colitis: a systematic review and meta-analysis. Inflamm Intest Dis. 2025;11:29\u201342.","journal-title":"Inflamm Intest Dis"},{"key":"1294_CR32","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.cgh.2022.03.008","volume":"21","author":"P Veyrard","year":"2023","unstructured":"Veyrard P, Pellet G, Laharie D, et al. Efficacy of induction therapy with calcineurin inhibitors in combination with ustekinumab for acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2023;21:1354-5.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1294_CR33","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/ecco-jcc\/jjad004","volume":"17","author":"JP Gisbert","year":"2023","unstructured":"Gisbert JP, Garc\u00eda MJ, Chaparro M. Rescue therapies for steroid-refractory acute severe ulcerative colitis: a review. J Crohns Colitis. 2023;17:972\u201394.","journal-title":"J Crohns Colitis"},{"key":"1294_CR34","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231218555","volume":"17","author":"F Vitali","year":"2023","unstructured":"Vitali F, Rath T, Klenske E, et al. Long-term outcomes of cyclosporin induction and ustekinumab maintenance combination therapy in patients with steroid-refractory acute severe ulcerative colitis. Ther Adv Gastroenterol. 2023;17:17562848231218555.","journal-title":"Ther Adv Gastroenterol"},{"key":"1294_CR35","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/ans.17439","volume":"92","author":"MW Trinder","year":"2022","unstructured":"Trinder MW, Clifford M, Jones AL, et al. The impact of sarcopenia on outcomes in patients with inflammatory bowel disease undergoing colorectal surgery. ANZ J Surg. 2022;92:397\u2013402.","journal-title":"ANZ J Surg"},{"key":"1294_CR36","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2468-1253(23)00313-8","volume":"9","author":"P Rivi\u00e8re","year":"2024","unstructured":"Rivi\u00e8re P, Li Wai Suen C, Chaparro M, et al. Acute severe\u00a0ulcerative colitis management: unanswered questions and latest insights. Lancet Gastroenterol Hepatol. 2024;9:251\u201362.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"1294_CR37","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/apt.16249","volume":"53","author":"P Sahu","year":"2021","unstructured":"Sahu P, Kedia S, Vuyyuru SK, et al. Randomised clinical trial: exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2021;53:568\u201376.","journal-title":"Aliment Pharmacol Ther"},{"key":"1294_CR38","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1111\/apt.15984","volume":"52","author":"PS Dulai","year":"2020","unstructured":"Dulai PS, Raffals LE, Hudesman D, et al. A phase 2B randomised trial of hyperbaric oxygen therapy for ulcerative colitis patients hospitalized for moderate to severe flares. Aliment Pharmacol Ther. 2020;52:955\u201363.","journal-title":"Aliment Pharmacol Ther"},{"key":"1294_CR39","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1007\/s10620-020-06707-3","volume":"66","author":"PS Dulai","year":"2021","unstructured":"Dulai PS, Jairath V. A microsimulation model to project the 5-year impact of using hyperbaric oxygen therapy for ulcerative colitis patients hospitalized for acute flares. Dig Dis Sci. 2021;66:3740\u201352.","journal-title":"Dig Dis Sci"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01294-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-026-01294-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01294-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T13:49:48Z","timestamp":1774964988000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-026-01294-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1294"],"URL":"https:\/\/doi.org\/10.1007\/s40266-026-01294-w","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"26 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"W.F., G.C., A.V. have no conflicts of interest relevant to the content of the paper. Walter Fries is an Editorial Board member of Drugs & Aging. Professor Fries was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors agree with the final version of the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability (software application or custom code)"}},{"value":"W.F., A.V. conceptualization, drafting, review and approval of the manuscript; G.C. review and approval of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors contribution"}}]}}